Articles On Immutep (ASX:IMM)

Title Source Codes Date
Major capital raise and new trial for Immutep

Australian immunotherapy company Immutep (ASX:IMM) has announced a $60 million capital raise and approval for a phase one clinical trial of its lead investigative candidate as part of a triple combination for the treatment of variou...

BiotechDispatch IMM 2 hours ago
ASX crashes over 2%: What fuelled sharp sell-off in the market

Summary The ASX dropped over 2% to hit intraday low of 7,216.60, led by sharp sell-off in financials, energy, and industrial stocks. The market sentiments were dented by the US Fed official comment that the central bank might raise int...

Kalkine Media IMM 23 hours ago
Why the Immutep (ASX:IMM) share price is sinking 16% today

The Immutep Ltd (ASX: IMM) share price has returned from its trading halt and is sinking lower on Monday morning. At the time of writing, the biotechnology company’s shares are down 16% to 51.5 cents. Despite this decline, the Immutep shar...

Motley Fool IMM 1 day ago
10 at 10: These ASX stocks are running wild this morning

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead IMM 1 day ago
ScoPo’s Powerplays: ‘Prepare for a big jump in July’ as tax-loss selling in healthcare continues

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week As we appro...

Stockhead IMM 3 days ago
Here’s why the Immutep (ASX:IMM) share price is frozen

For the second day in a row, the Immutep Ltd (ASX: IMM) share price will be frozen at market open. Yesterday, Immutep entered a trading halt until Monday’s open, or until such time as the company releases further news regarding a capital r...

Motley Fool IMM 4 days ago
Last Orders: ASX falls despite strong jobs data

The ASX plummeted into the red today despite positive jobs data out of the ABS, which showed unemployment falling for the seventh straight month to 5.1% while 115,000 jobs were added. This job growth was offset by the growing COVID outbreak...

Stockhead IMM 4 days ago
Immutep drafts in Bell Potter, Jefferies for raising

Cancer and auto-immune disease drug developer Immutep landed in front of fund managers on Thursday morning with a capital raising.

AFR IMM 5 days ago
ScoPo’s Powerplays: Biogen drama, M&A action, and profit-taking coloured the week in healthcare

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week Healthcare...

Stockhead IMM 1 week ago
‘Miracle’ breakthrough in melanoma fight puts focus on ASX stocks in the skin cancer space

There’s no two ways about it, melanoma kills, especially here in Australia. We have one of the highest rates of melanoma in the world, and melanoma is often referred to as ‘Australia’s national cancer’. Around 16,000 Australians are diagnos...

Stockhead IMM 1 week ago
Alzheimer’s Decision Sends Positive Message to Aussie Biotechs

ShareCafeAlzheimer’s Decision Sends Positive Message to Aussie Biotechs The US Food and Drug Administration’s landmark but controversial approval of a new treatment for Alzheimer’s disease suggests a sea change in the regulator’s attitude t...

ShareCafe IMM 1 week ago
Check Up: As Alzheimer’s grabs the spotlight, these ASX biotech stocks also impressed

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Stockhead IMM 1 week ago
ASX hits a new high on realty, tech boost: What lies ahead for market

Summary The ASX 200 hit a fresh high of 7,315.60 on Tuesday amid broad-based buying. The index was trading 17.40 points or 0.24% higher at 7,299.30 by the afternoon. The top five gainers on the ASX are Mesoblast, EML Payments, Whiteha...

Kalkine Media IMM 1 week ago
Why the Immutep (ASX:IMM) share price is marching higher today

The Immutep Ltd (ASX: IMM) share price jumped by more than 5% in morning trade to 69 cents following an update on the company’s preclinical development of a tablet to treat cancer. The Immutep share price has since pulled back slightly and...

Motley Fool IMM 1 week ago
Immutep reports final data from phase one study of LAG-3 Therapy

Immutep (ASX:IMM), a company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune disease, has announced what it describes as "encouraging final data" from its phase one INSIGHT-004 study.

BiotechDispatch IMM 2 weeks ago
Market highlights and 5 ASX small caps to watch on Tuesday

Wall Street mixed as AMC gets pumped again Major indices in the US were mixed last night, ahead of Thursday’s US inflation report for May. The Dow Jones fell by 0.36%, S&P 500 was down by 0.08%, while tech-heavy Nasdaq was up by 0.49%....

Stockhead IMM 2 weeks ago
ASX dream run continues, hits a new high; energy stocks lead 

Summary The ASX 200 continued gaining momentum on Thursday, hitting a fresh record high. The market sentiment got a lift after trade balance and retail sales both rose in April. Energy stocks emerge as top gainers, owing to a rise in...

Kalkine Media IMM 2 weeks ago
Immutep (ASX:IMM) share price backtracks despite patent approval

The Immutep Ltd (ASX: IMM) share price slipped today, despite the biotechnology company announcing it has secured another European patent. At market close, the Immutep share price finished the day 0.71%lower at 69.5 cents. Immutep further...

Motley Fool IMM 2 weeks ago
May Winners Column: Uranium, biotechs and real estate takeover targets put in the hard yards on the ASX

Last month, the ASX finally reached its pre-pandemic high, went in circles for a couple of weeks then reached it again. What else happened in May? Well, the phase “To the moon” obtained its traditional meaning once more. While the phase has...

Stockhead IMM 2 weeks ago
Immutep (ASX:IMM) share price bounces on new supply deal

The Immutep Ltd (ASX: IMM) share price is bouncing around today after the biotechnology company announced it has teamed up with a new German partner for a cancer study. After rising and falling several times during early trade, Immutep sha...

Motley Fool IMM 3 weeks ago
Immutep announces new collaboration with Merck

Immunotherapy company Immutep (ASX:IMM) has announced a new collaboration and supply agreement with German company Merck for a Phase 1/2a clinical trial in patients with solid tumours.

BiotechDispatch IMM 3 weeks ago
Market highlights and 5 ASX small caps to watch on Tuesday

Iron ore pushes back near US$200/tonne again The US and UK stock markets were closed on Monday for the long weekend public holiday. According to the OECD, the US economy is set to grow at the fastest rate since 1984, thanks to the governmen...

Stockhead IMM 3 weeks ago
ScoPo’s Powerplays: The immune oncology space finally gets long overdue attention

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Stockhead IMM 3 weeks ago
New China patent for Immutep's eftilagimod alpha

Immutep (ASX:IMM), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, has announced the Chinese Patent Office has awarded a new patient for eftilagimod alpha.

BiotechDispatch IMM 3 weeks ago
ASX in red: Will market snap a 3-session winning streak?

Summary The ASX 200 is trading lower by 8.60 points or 0.12% to 7,106.60 at the close, weighed down by energy and mining stocks. The healthcare sector was the worst performer, falling 0.87%, followed by energy, materials, and A-REIT....

Kalkine Media IMM 3 weeks ago
Why the Immutep (ASX:IMM) share price rocketed 14% today

The Immutep Ltd (ASX: IMM) share price finished strongly today. This came after the company announced it has been granted a new Chinese patent. At close of trading today, the biotechnology company’s shares were trading at 67 cents, up 13.5...

Motley Fool IMM 3 weeks ago
Invion led a group of ASX cancer stocks up after promising news

It was a good day for some of ASX-listed cancer therapy stocks yesterday, with three companies releasing seperate announcements that sent their share prices higher. Cancer therapy stocks Invion (ASX:IVX), Immutep (ASX:IMM), and Imugene (ASX...

Stockhead IMM 3 weeks ago
ASX Gains Amid Choppy Trade, Healthcare, Energy Stocks in High Spirits

Summary The ASX 200 trades higher by 15.20 points or 0.22% to 7045.50 at the close, led by gains in heavyweight healthcare and energy stocks. Retail player Kogan.Com and gold miner Silver Lake Resources are top performing stocks on the...

Kalkine Media IMM 4 weeks ago
Hot Money Monday: Global Health leads the pack as biotech heat up

Biotech Global Health (ASX:GLH) topped this week’s Running Hot list, in the wake of more steady gains in May which has seen its share price rise by almost 500 per cent over the past 12 months. Each week, Stockhead recaps ASX stocks that are...

Stockhead IMM 4 weeks ago
ScoPo’s Powerplays: Hearing tech, medical devices to ride out choppy market

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week Healthcare...

Stockhead IMM 1 month ago
ASX set to close higher on tech rally, gets a boost from robust sales data

Summary The ASX 200 is set to close the week with narrow gains, led by a strong rally in healthcare and tech stocks. The top five gainers on the ASX are EML Payments, A2 Milk Company, Webjet, Nuix and Xero. Bitcoin staged a smart reco...

Kalkine Media IMM 1 month ago
ASX reclaims 7000 mark on financial, tech boost; Afterpay jumps 7%

Summary The ASX 200 gained 89.50 points or 1.29% to 7021.20 amid broad-based buying. Nine of the 11 sectors traded in the green, while tech stocks lead the pack with a 4.32% gain.  Afterpay emerges as the top gainer, followed by Redbu...

Kalkine Media IMM 1 month ago
ASX records worst performance in three months; EML Payments crashes 45% 

Summary The ASX 200 is heading towards its worst performance since late February, down 2% at 6924.10 at the close. The market breadth was extremely week, with all the 11 sectoral indices trading in red. EML Payments shares plunged ove...

Kalkine Media IMM 1 month ago
Three ASX healthcare stocks that are trending today – ILA, 1AD and PAR

Summary Island Pharmaceuticals and AdAlta have obtained patent protection for their lead programs in the US and Japan, respectively. Paradigm Biopharmaceuticals has received first revenue through a physician prescription of Zilosul®....

Kalkine Media IMM 1 month ago
Immutep Shares Hold Steady despite Operational Update (ASX:IMM)

Cancer immunotherapy developer Immutep Ltd [ASX:IMM] share price is trading neutral at time of writing, holding steady after flip-flopping between earlier gains and losses... The post Immutep Shares Hold Steady despite Operational Update (A...

MoneyMorning IMM 1 month ago
Last Orders: ASX 200 rebounds, but the IT sector slumps 10 per cent for the week

The ASX 200 has rebounded from yesterday’s loss though the technology sector has weighed on the market for two consecutive weeks. The index closed 0.20 per cent higher, and is also up by 0.70 per cent for the week. IT slumped by another 2.5...

Stockhead IMM 1 month ago
Immutep: A leader in a league alongside global Pharma giants

ShareCafeImmutep: A leader in a league alongside global Pharma giants Immutep (IMM.ASX) is one of the most promising drug developers listed on the ASX. The company’s lead product candidate is eftilagimod alpha (LAG-3Ig or IMP321), which is...

ShareCafe IMM 1 month ago
ScoPo’s powerplays: Antisense ‘looks like it wants to run harder’

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Themes of the week The ASX he...

Stockhead IMM 2 months ago
Immutep Share Price Soars on US FDA Fast Track Designation (ASX:IMM)

The Immutep Ltd [ASX:IMM] share price is up 11.4% today after securing fast track designation from the US FDA for its eftilagimod alpha product. IMM shares were up as much as 17% in early trade... The post Immutep Share Price Soars on US F...

MoneyMorning IMM 2 months ago
Immutep (ASX:IMM) receives fast track approval for lead product 'efti'

08 April 2021 - Biotechnology company Immutep (ASX:IMM) has received a fast-track approval from the United States Food and Drug Administration (FDA) for its lead product ‘efti’.

FNN IMM 2 months ago
Immutep up 11pc on US fast-track designation for lead drug candidate

Immutep (ASX:IMM) shares have hit their highest level in early trade after the Sydney biotech company’s lead product candidate was green-lit for possible early regulatory approval in the United States. Immutep’s drug candidate eftilagimod a...

Stockhead IMM 2 months ago
Why Creso, EML, Immutep, & Western Areas shares are storming higher

In late morning trade the S&P/ASX 200 Index (ASX: XJO) is on form again and charging higher. At the time of writing, the benchmark index is up 1.1% to 7,006.3 points. Four ASX shares that are climbing more than most today are listed be...

Motley Fool IMM 2 months ago
ASX 200 today: What’s driving Australian shares today?

Source:Khakimullin, Shutterstock Summary The ASX 200 on Thursday opened higher, up 13.70 points, or 0.20%, to 6,941.70, even as the US stock markets closed mixed overnight.   Metals & Mining and Resources were up by over 1%...

Kalkine Media IMM 2 months ago
Here’s why the Immutep (ASX:IMM) share price is rocketing 10% higher

The Immutep Ltd (ASX: IMM) share price has been a strong performer again on Thursday. In morning trade, the biotechnology company’s shares are storming 10% higher to 48.5 cents. Why is the Immutep share price storming higher? Investors hav...

Motley Fool IMM 2 months ago
FDA fast track designation for Immutep's 'efti'

Immutep (ASX:IMM) has announced that the US FDA has granted fast-designation to its lead product candidate eftilagimod alpha.

BiotechDispatch IMM 2 months ago
Market highlights and 4 ASX small caps to watch on Thursday

S&P 500 at record high again, after release of Fed minutes S&P 500 has set a record high again, marking the 18th time it has done so this year. The index rose by 0.15%, after the Fed said it will continue ultra-low interest rates po...

Stockhead IMM 2 months ago
How Nexion Group (ASX:NNG) would benefit from Blue Sky Telecom acquisition

Source:elwynn, Shutterstock Summary Nexion Group Ltd (ASX:NNG) on Thursday announced that it had completed agreement to acquire Blue Sky Telecom Pty Ltd as part of its growth strategy. The agreement to acquire 100 per cent of the issu...

Kalkine Media IMM 2 months ago
Why Immutep (ASX:IMM) shares could be under watch today?

Source:Khakimullin , Shutterstock Summary Immutep Ltd (ASX:IMM) announced that its lead product candidate eftilagimod alpha or efti had received fast track designation from the United States Food and Drug Administration (FDA). Efti ha...

Kalkine Media IMM 2 months ago
3 Australian healthcare shares on the rise – BDA, MXC and IMM

Source: DG PhotoStock, Shutterstock Summary ASX-cannabis player Bod Australia has obtained a binding purchase order (PO) for CBD products in the US. Another cannabis player, MGC Pharmaceuticals, has completed the delivery of the first...

Kalkine Media IMM 2 months ago
Here’s why the Immutep (ASX:IMM) share price is climbing today

The Immutep Ltd (ASX: IMM) share price is climbing in late-morning trade after announcing a new European patent grant. At the time of writing, the biotechnology company’s shares are swapping hands for 44 cents, up 2.35%. What was announced...

Motley Fool IMM 2 months ago